The reason for this extension is to evaluate the long-term safety and efficacy of two
concentration-controlled everolimus regimen in de novo liver transplant recipients. The most
important long-term safety assessments include evaluation of renal function, progression of
HCV related allograft fibrosis, and other treatment related effects at Month 36
post-transplantation compared to extension baseline (Months 24 post-transplantation).
Minimum age: 20 Years.
Maximum age: 75 Years.
Gender(s): Both.
Novartis Investigative Site, Gent 9000, Belgium
Novartis Investigative Site, Leuven 3000, Belgium
Novartis Investigative Site, Liege 4000, Belgium
Novartis Investigative Site, Bogotá, Colombia
Novartis Investigative Site, Cali, Colombia
Novartis Investigative Site, Praha 4 140 21, Czech Republic
Novartis Investigative Site, Bordeaux Cedex 33076, France
Novartis Investigative Site, Clichy 92110, France
Novartis Investigative Site, Creteil 94010, France
Novartis Investigative Site, Marseille 13385, France
Novartis Investigative Site, Montpellier 34295, France
Novartis Investigative Site, Villejuif 94805, France
Novartis Investigative Site, Berlin 13353, Germany
Novartis Investigative Site, Essen 45147, Germany
Novartis Investigative Site, Hamburg 20246, Germany
Novartis Investigative Site, Heidelberg 69120, Germany
Novartis Investigative Site, Leipzig 04103, Germany
Novartis Investigative Site, Mainz 55131, Germany
Novartis Investigative Site, Regensburg 93053, Germany
Novartis Investigative Site, Dublin 4, Ireland
Novartis Investigative Site, Rotterdam 3015 CE, Netherlands
Novartis Investigative Site, Moscow 123182, Russian Federation
Novartis Investigative Site, Moscow 129010, Russian Federation
Novartis Investigative Site, Stockholm 141 86, Sweden
Novartis Investigative Site, Edinburgh EH16 4SA, United Kingdom
Novartis Investigative Site, Hospitalet de Llobregat, Barcelona 08907, Spain
Novartis Investigative Site, Caba, Buenos Aires C1118AAT, Argentina
Novartis Investigative Site, San Martin, Buenos Aires C1107BEA, Argentina
Novartis Investigative Site, Barcelona, Catalunya 08035, Spain
Novartis Investigative Site, Barcelona, Catalunya 08036, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana 46026, Spain
Novartis Investigative Site, Washington, District of Columbia 20007-2197, United States
Novartis Investigative Site, Tampa, Florida 33606, United States
Novartis Investigative Site, Lexington, Kentucky 40536-0293, United States
Novartis Investigative Site, Milano, MI 20162, Italy
Novartis Investigative Site, Modena, MO 41100, Italy
Novartis Investigative Site, Detroit, Michigan 48202-2689, United States
Novartis Investigative Site, Rochester, Minnesota 55905, United States
Novartis Investigative Site, St. Louis, Missouri 63110, United States
Novartis Investigative Site, Newark, New Jersey 07101, United States
Novartis Investigative Site, Camperdown, New South Wales 2050, Australia
Novartis Investigative Site, New York, New York 10016, United States
Novartis Investigative Site, New York, New York 10032, United States
Novartis Investigative Site, Chapel Hill, North Carolina 27599, United States
Novartis Investigative Site, Durham, North Carolina 27710, United States
Novartis Investigative Site, Oklahoma City, Oklahoma 73112, United States
Novartis Investigative Site, Pisa, PI 56124, Italy
Novartis Investigative Site, Baracaldo, Pais Vasco 48903, Spain
Novartis Investigative Site, Rio de Janeiro, RJ 21041-030, Brazil
Novartis Investigative Site, Roma, RM 00161, Italy
Novartis Investigative Site, Porto Alegre, RS 90020-090, Brazil
Novartis Investigative Site, Bedford Park, South Australia 5042, Australia
Novartis Investigative Site, Charleston, South Carolina 29425, United States
Novartis Investigative Site, Torino, TO 10126, Italy
Novartis Investigative Site, Houston, Texas 77030-2400, United States
Novartis Investigative Site, Houston, Texas 77030, United States
Novartis Investigative Site, Heidelberg, Victoria 3084, Australia